Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00683644
Other study ID # 200603807
Secondary ID
Status Completed
Phase Phase 2
First received May 21, 2008
Last updated November 10, 2017
Start date January 2008
Est. completion date December 2011

Study information

Verified date November 2017
Source University of Iowa
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

There is widespread belief and some evidence to indicate that zinc can successfully treat tinnitus. Zinc deficiency is more likely to occur in the elderly . The primary objective of this study is to establish the effectiveness of zinc for the treatment of tinnitus in individuals 60 years of age and older. Subjects will be randomly assigned to either receive zinc daily or a placebo. After 4 months and a 1-month wash-out, the subjects will be crossed over to the other group.


Description:

There is widespread belief and some evidence to indicate that zinc can successfully treat tinnitus. Zinc deficiency is more likely to occur in the elderly . The primary objective of this study is to establish the effectiveness of zinc for the treatment of tinnitus in individuals 60 years of age and older. Subjects will be randomly assigned to either receive zinc daily or a placebo. After 4 months and a 1-month wash-out, the subjects will be crossed over to the other group. 116 patients were tested. Tinnitus loudness and the Tinnitus Handicap Questionnaire are the outcome measures.


Recruitment information / eligibility

Status Completed
Enrollment 116
Est. completion date December 2011
Est. primary completion date December 2011
Accepts healthy volunteers No
Gender All
Age group 60 Years and older
Eligibility Inclusion Criteria:

- 60 years of age or older

- Tinnitus for 6 months or more

- Normal copper levels

- Be generally healthy

Exclusion Criteria:

- Have a treatable otological disorder

- Involved in litigation

- Have or are suspected of having a serious psychiatric problem

- Involved in other treatments for tinnitus

- Are taking drugs which might interact with zinc and result in tinnitus

- Have copper deficiency

- Have Zinc levels above normal

- Are cognitively impaired.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Zinc
Zinc taken once daily
Placebo oral capsule
Placebo capsules taken once daily

Locations

Country Name City State
United States University of Iowa Iowa City Iowa

Sponsors (2)

Lead Sponsor Collaborator
University of Iowa Tinnitus Research Initiative

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline in Tinnitus Reaction on the Tinnitus Handicap Questionnaire Scores (0-100) at 4 Months Validated questionnaire of tinnitus reactions. Scale 0 (no tinnitus reaction)- 100 (worst tinnitus reaction). Our primary outcome was the difference scores between Tinnitus Handicap Questionnaire (THQ) on baseline and end of treatment on zinc and placebo treatment. As stated by Newman et al., the test-retest variability was 20%, and difference scores greater than this should be considered a significant reduction. Therefore, changes on the difference scores of 20 or greater were considered as a statistically significant and therefore clinically meaningful improvement for THQ. The minimum score is zero and the maximum is 100. 0 is better and 100 is worse. This applies to all outcome measures. baseline - 4 months
Secondary Changes on Baseline Tinnitus Magnitude on Tinnitus Loudness Rating Scores (0-100) at 4 Months Treatment Participants should rate their tinnitus loudness on a scale of 0 (no perception of tinnitus) to 100 (highest degree of tinnitus perception). baseline and 4 months
Secondary Changes on Baseline Tinnitus Reactions on Tinnitus Annoyance Rating Scores (0-100) at 4 Months Treatment Tinnitus annoyance rate on a scale of 0 (no annoyance) to 100 (maximum degree of annoyance) baseline and 4 months
See also
  Status Clinical Trial Phase
Recruiting NCT05963542 - Efficacy of Online Acceptance and Commitment Therapy and Sound Therapy for Patients With Tinnitus and Insomnia N/A
Recruiting NCT04987502 - Virtual Reality and Subjective Tinnitus N/A
Recruiting NCT04404439 - Treatment of Tinnitus With Migraine Medications Phase 4
Recruiting NCT05533840 - Establishment and Application of a New Imaging System for Otology Based on Ultra-high Resolution CT
Completed NCT03552302 - Effects of Yoga Exercise on Participates With Tinnitus
Enrolling by invitation NCT02617953 - Objective Diagnosis Method and Efficacy of Repetitive Transcranial Magnetic Stimulation as a Treatment for Tinnitus N/A
Withdrawn NCT01663467 - Efficacy of Internet and Smartphone Application-delivered Tinnitus Retraining Therapy N/A
Completed NCT02269839 - A Feasibility Study Assessing the Effectiveness of rTMS in Tinnitus N/A
Completed NCT02974543 - Somatosensory Stimulation to Alleviate Tinnitus N/A
Completed NCT01929837 - Tinnitus rTMS 2013 N/A
Completed NCT01857661 - The Influence of the Sound Generator Combined With Conventional Amplification for Tinnitus Control: Blind Randomized Clinical Trial N/A
Completed NCT01927991 - Internet-based Self-help for Tinnitus: The Role of Support N/A
Completed NCT01480193 - New Therapy for Patients With Severe Tinnitus N/A
Terminated NCT01412918 - Inhibitor Masking Device & Sodium Channel, Voltage Gated, Type IX Alpha Subunit (SCN9) Gene Expression N/A
Completed NCT00748475 - Countering Stimulus-Induced Alpha-Desynchronization to Treat Tinnitus N/A
Completed NCT00371436 - Progressive Intervention Program for Tinnitus Management N/A
Completed NCT00733044 - Cost-effectiveness of Multidisciplinary Management of Tinnitus N/A
Active, not recruiting NCT05518682 - Assessment of Bimodal Stimulation Device Compliance and Satisfaction in Individuals With Tinnitus N/A
Recruiting NCT05212298 - Effects of Herbal Sleep Formula on Patients With Insomnia and Tinnitus N/A
Completed NCT06025097 - Intra-Tympanic Steroid With PRP Combination in Sensorineural Hearing Loss and Tinnitus. Early Phase 1